37MO Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: Overall survival (OS) by MMR status and molecular subgroups
Authors:
- M.A. PowellMPM.A. Powell
- A. AuranenAAA. Auranen
- L.J. WillmottLWL.J. Willmott
- L. GilbertLGL. Gilbert
- D. BlackDBD. Black
- D. CibulaDCD. Cibula
- S. SharmaSSS. Sharma
- G. ValabregaGVG. Valabrega
- L.M. LandrumLLL.M. Landrum
- L.C. HankerLHL.C. Hanker
- A. StuckeyASA. Stuckey
- I.A. BoereIBI.A. Boere
Open Access
Abstract
No abstract availableFunding Information
- GlaxoSmithKline